Antares Pharma Shares Rise After FDA Approves First Rival Generic EpiPen
2018年8月17日 - 6:54AM
Dow Jones News
By Stephen Nakrosis
Shares of Antares Pharma Inc. (ATRS) are rising after-hours
Thursday, the day the U.S. Food and Drug Administration approved
Teva Pharmaceutical Industries' generic auto-injector with
epinephrine, a device that utilizes Antares' Vibex auto injector
platform. This was the first time the FDA approved a generic
substitute for Mylan's EpiPen injector device.
Antares said the company "previously entered into an exclusive
License, Development and Supply Agreement with Teva for an
epinephrine auto injector product to be marketed in the U.S." In
line with the agreement, Antares will supply the device, and Teva
will be responsible for commercialization and distribution of the
final product. Antares will receive royalties on net sales, the
company said.
Shares of Antares closed Thursday trading at $3.30, up 4.10% on
heavy volume. IN after-hours trading, shares were up 3.03% at
$3.40. (stephen.nakrosis@wsj.com)
(END) Dow Jones Newswires
August 16, 2018 17:39 ET (21:39 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024